Drug Sponsors

Medivir restructures, partners with GVK BIO

Wednesday, June 17, 2015


Medivir,
a research based pharmaceutical company based in Sweden, has announced a reorganization within its Discovery Research department, increasing its focus within the core areas of oncology and infectious diseases, and a partnership with GVK Biosciences Private (GVK BIO) of Hyderabad in India, designed to deliver enhanced efficiency and quality within its portfolio of research projects while over time reducing overall research costs and enhancing future cost flexibility.

[Read More]

GSK launches Altius Institute for Biomedical Sciences

Wednesday, June 17, 2015

GlaxoSmithKline is launching the Altius Institute for Biomedical Sciences, an independent, nonprofit research institute in Seattle. Altius will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions in health and disease. GSK expects to capitalize on rapid progress in understanding gene control to select and validate better drug targets, and to accelerate many key aspects of developing new medicines.

[Read More]

Pharma industry improves its tarnished reputation

Monday, June 15, 2015

The reputation of the pharmaceutical industry—historically not much better than that of the oil or tobacco industries—has stabilized in recent years. And public views about clinical research have improved significantly. Yet overall, the level of trust in pharmaceutical companies remains low.

[Read More]

Roswell Park Cancer Institute spins out new company OmniSeq

Friday, June 12, 2015

OmniSeq has officially begun its spin out from Roswell Park Cancer Institute (RPCI) and will immediately begin commercializing its suite of innovative products that support a physician-driven, collaborative approach to genomic diagnostics—matching cancer patients to therapies tailored specifically to them. Collectively known as OmniSeq Precision Medicine Technology, OmniSeq provides oncology groups, hospitals and healthcare systems with the first-ever fusion of clinical genomics and a comprehensive information technology solution that provides easy access to actionable insights about their patient’s condition and available treatment options. Like Roswell Park, OmniSeq is based in Buffalo, N.Y.

[Read More]

Altan Pharma acquires Spain-based pharma GES Group

Friday, June 12, 2015

Altan Pharma, an Irish specialty pharmaceutical company has acquired a privately held group of Spanish companies, The GES Group. The GES Group develops, manufactures and markets specialty injectable drugs. GES, headquartered in Spain, is comprised of three operating companies: GES Genéricos Españoles Laboratorio, Genfarma Laboratorio and Biomendi. 

[Read More]

Panasonic Healthcare acquires Bayer Diabetes

Wednesday, June 10, 2015

Panasonic Healthcare Holdings (PHCHD), based in Tokyo, has inked an agreement to acquire Bayer Diabetes Care (BDC) for $1.2 billion to create a global diabetes care solutions business. BDC is a provider of blood glucose monitoring systems to people with diabetes and healthcare professionals around the world. It was formed as a business unit within Bayer and is present in more than 125 countries. It generated sales of $1 billion in 2014.

[Read More]